AMGEN INC (AMGN) earnings date
Feb 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 2 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | after close | 34 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | after close | 30 | 8-K |
| Q4 FY2025 | Tue, Feb 3, 2026 | after close | 34 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | after close | 31 | 8-K |
| Q4 FY2024 | Tue, Feb 4, 2025 | after close | 35 | 8-K |
What they guided beta
| Q3 FY2026 | "TEPEZZA ® (teprotumumab-trbw) sales decreased 6% year-over-year to $526 million in the third quarter, driven by lower inventory levels." exhibit |
| Q3 FY2026 | "TAVNEOS ® (avacopan) sales decreased 2% year-over-year to $105 million in the third quarter, driven by 9% lower volume, 8% unfavorable changes to estimated sales deductions and 5% lower net selling price, partially offset by higher inventory levels." exhibit |
| Q3 FY2026 | "Otezla ® (apremilast) sales decreased 18% year-over-year to $481 million in the third quarter, driven by 13% lower volume, 9% unfavorable changes to estimated sales deductions and 4% lower net selling price, partially offset by higher inventory levels." exhibit |
| Q3 FY2026 | "Enbrel ® (etanercept) sales increased 5% year-over-year to $611 million in the third quarter, driven by 15% favorable changes to estimated sales deductions and 8% higher inventory levels, partially offset by 14% lower net selling price, reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the Inflation Reduction Act, and lower volume." exhibit |
| Q3 FY2026 | "PAVBLU ® (aflibercept-ayyh) sales increased 41% year-over-year to $300 million in the third quarter, driven by 71% volume growth, partially offset by 18% lower net selling price." exhibit |
| Q2 FY2026 | "Prolia ® (denosumab) sales decreased 32% year-over-year to $759 million in the second quarter, driven by 20% lower volume and 12% lower net selling price as multiple biosimilars have launched globally with more biosimilars expected." exhibit |
| Q2 FY2026 | "KRYSTEXXA ® (pegloticase) sales increased 15% year-over-year to $400 million in the second quarter, driven by 23% higher net selling price, partially offset by lower inventory levels." exhibit |
| Q2 FY2026 | "Otezla ® (apremilast) sales decreased 21% year-over-year to $491 million in the second quarter, primarily driven by 9% lower net selling price and 6% lower volume." exhibit |
| Q2 FY2026 | "Enbrel ® (etanercept) sales decreased 4% year-over-year to $580 million in the second quarter, primarily driven by 22% lower net selling price, partially offset by 16% favorable changes to estimated sales deductions." exhibit |
| Q2 FY2026 | "KYPROLIS ® (carfilzomib) sales decreased 17% year-over-year to $314 million in the second quarter, driven by lower volume." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AMGN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AMGN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AMGN/"><img src="https://veritasdata.dev/embed/AMGN.svg" alt="AMGN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AMGN/)
Script
<script async src="https://veritasdata.dev/embed/AMGN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AMGN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.